IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

NCT01234974 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study never undertaken

Conditions

Multiple Myeloma

Interventions

DRUG: Pasireotide
DRUG: Everolimus

Sponsor

Milton S. Hershey Medical Center